Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

769.88 +4.20 (+0.55%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout
Via The Motley Fool
Peering Into Eli Lilly's Recent Short Interest
Via Benzinga
Behind the Scenes of Eli Lilly's Latest Options Trends
Via Benzinga
15 Billion Reasons to Love Eli Lilly Stock Right Now
Lilly just gave investors more reasons to cheer the company on. 
Via The Motley Fool
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
Via Investor's Business Daily
2 Brand-New Reasons to Buy Eli Lilly Stock Right Now, and 2 Reasons to Be Cautious
Via The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Eli Lilly Unusual Options Activity
Via Benzinga
Did Eli Lilly Just Say "Checkmate" to Novo Nordisk?
Via The Motley Fool
2 Weight Loss Stocks That Are Screaming Buys in December
Via The Motley Fool
3 Unstoppable Stocks to Buy Right Now
Via The Motley Fool
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs
Novo Nordisk's Ozempic Label Expansion Snags Approval From European Drug Regulator's Advisory Panel
Novo Nordisk's Ozempic gains positive EMA opinion for label update after FLOW trial data show significant kidney and cardiovascular risk reduction. 
Via Benzinga
Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an integrated platform with home delivery. 
Via Benzinga
Eli Lilly Stock Could Have a Huge Growth Catalyst in Early 2025
Via The Motley Fool
2 No-Brainer Growth Stocks to Buy and Hold Through 2025 and Beyond
Via The Motley Fool
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Eli Lilly's Phase 3 EMBER-3 trial shows imlunestrant improves progression-free survival in advanced ER+ breast cancer patients with ESR1 mutations. 
Via Benzinga
4 Stocks That Crushed Analyst Estimates by More Than Double
Hims & Hers, Alcoa, Vicor, and Stride crushed earnings with massive EPS beats. See what’s driving their growth and future potential. 
Via MarketBeat
Eli Lilly's $15 Billion Buyback Faces Stiff Resistance On The Charts
Eli Lilly announces $15 billion share buyback plan and 15% dividend boost amidst mixed technical signals. Investors are skeptical. 
Via Benzinga
What's Going On With Eli Lilly Stock On Tuesday?
Eli Lilly's BRUIN CLL-321 trial shows pirtobrutinib improves outcomes in CLL/SLL patients, offering longer progression-free survival and lower relapse risk. 
Via Benzinga
As Eli Lilly Shares Gain Over 35% YTD, Drugmaker Announces $15B Share Buyback Program And Boosts Dividend By 15%
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open market and privately negotiated transactions. 
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties. 
Via Benzinga
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
BioAge Labs halts STRIDES Phase 2 trial of azelaprag after liver enzyme elevations, plans further analysis with updates expected in Q1 2025. 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Via The Motley Fool
MarketBeat Week in Review – 12/2 - 12/6
Equities continued their post-election rally after Friday’s solid November jobs report and all signs point to the rally in stocks extending into 2025 
Via MarketBeat
Topics Economy Government Immigration
Exposures Economy Immigration Interest Rates
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Eli Lilly Stock Price Analysis – Earnings Miss And The Pullback Worth Watching
The company lowered its FY2024 guidance following Q3 earnings, citing supply chain challenges for top-selling drugs like Mounjaro and Zepbound and a one-time R&D expense from its $3.2 billion... 
Via Talk Markets
Topics Earnings Economy Stocks / Equities
Exposures Financial Supply Chain
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity for critical medicines with advanced automation. 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.